Elevation of ELISA D-dimer levels in patients with primary pulmonary hypertension

Respiration

Volumn 69, Issue 4, 2002, Pages 327-329

  Shitrit, D ^a,b   Bendayan, D ^a,b   Rudensky, B ^c   Izbicki, G ^a,b   Huerta, M ^c   Fink, G ^a,b   Kramer, M R ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

ELISA D dimer; Primary pulmonary hypertension

Indexed keywords

D DIMER; ILOPROST; PROSTACYCLIN; UNIPROST;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYMPTOM;

ADULT; AGED; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED;

EID: 0036057134     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063270     Document Type: Article

References (18)

1. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
2. Prothrombotic mechanisms in primary pulmonary hypertension
3. Altered hemostasis in pulmonary hypertension
4. The role of thrombosis in severe pulmonary hypertension
5. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension
6. Clinical insights into the pathogenesis of primary pulmonary hypertension
7. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension
8. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension
9. Primary pulmonary hypertension
10. Primary pulmonary hypertension. Clinical and hemodynamic study
11. Primary pulmonary hypertension: Natural history and the importance of thrombosis
12. Primary pulmonary hypertension
13. Thrombotic lesions in primary plexogenic arteriopathy
14. Pathophysiology of primary pulmonary hypertension: From physiology to molecular mechanisms
15. Abnormal fibrinolysis in familial pulmonary hypertension
16. Pharmacodynamic profile of prostacyclin
17. Reduction in pulmonary vascular resistance with long term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
18. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension